Vorsetuzumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | CD70 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1165740-62-4 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6476H10006N1726O2028S50 |
| Molar mass | 146.1 kg/mol |
Vorsetuzumab is a monoclonal antibody developed by Seattle Genetics, designed for the treatment of cancer.[1]
Chemical names are:
- Immunoglobulin G1, anti-(CD antigen CD70) (human-mouse monoclonal h1F6 heavy chain), disulfide with human-mouse monoclonal h1F6 light chain, dimer
- Immunoglobulin G1, anti-(human CD70 antigen (CD27 ligand, Tumor necrosis
See also
References
This article is issued from Wikipedia - version of the 6/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.